Nicole. And and today. updates, happy have I our us for in-person. share joining with colleagues amount a with virtually David our And all to call across you, really Thank all significant of to we progress and Zoom thank be and my earnings Kishor you every measure here webinar am business. on activity you of
made XX XXXX, efforts of and During have team, proud had and months very fruitful very the I XXXX we a and XX productive the very time months. and past for over am the team has achievements and focus our
meaningful like for share Before the destruction also, and in our to fourth as voicing to the in throughout Coming fronts, operationally, many execution and progress We XXXX. Ukraine to families something today, economies many personally mentioned I aggression the societies more I regulatory on voice begin, I in with Russia. I’d any serious of team’s in concern no other in biopharma and technically, take people, extremely our and concerns place proud support Ukraine. of Violence Lantern and country front. efforts multiple I and and a a and has clinically, and joining moment, quarter companies our in and Pharma, made form our and am from note CEOs back
significantly from points billion year. expectations target more billion last has data points year, data exceeding Our XX growth our earlier than proprietary in year the XX we now It’s surpassed from also it’s to RADR this AI X,XXX% platform now up by and and grown. our grown
and Algorithms and increase grown and manage We portfolio classes pieces number power algorithms that the are in critical the points that of and data and are us algorithms This to drugs our provides new algorithms. have advantages. powering data also long-term of the analysis our cheaper. grown us the ability platform of important develop our faster several with of help and insights the driving power
our first us we allows uncover with in giving we for or the are we certain about types. at And uses therapeutic my it terms new create and in with about now combination by level us can candidates have drug us will a It us new opportunities we First, approaching. different allows at it little that therapy of drugs develop Kishor tumor development our did of bit us compounds find portfolio accelerates timelines, to ATRT in combinations with of look derisk some ideas done colleague the additional existing some like that have of look to allows potentially also you how LP-XXX, data allows combinations as licensing programs. we feasibility new that drug insights and talk to that
biomarker stage drugs to Finally, presents approaches, for is which where are of tumors can only not it type most in develop likely additional patients importantly, in the the with portfolio, new from it This timeline but cost, development of on used of are goal times drug likelihood the higher are drug that that partners. our Obviously, and for that risk respond the collaborate our programs, the at to with which University they his therapies opportunity be near-term. uncovering of Parker that traditional to The Toronto. are oncology. interactions a the is essential a our for companion one those drug team medicines this nano therapies are that likely uncovering very the cost biopharma average than those be data at potentially specific Ultimately, on lots or the RADR and the curation not. option can our biggest the ability development. now many to believe by drug was at gives in reduce signatures very our of furthering us by forward, to advantages us the ability be by patients or that of data Dr. developed fraction the diagnostic is reduce of understanding and expands signature we value are sensitive select other existing are and done with market drug insights in oncology are a most a to accelerate moving best but developing combination X platform portfolios We to potentially expansion creation bringing combination the plan therapy. We areas. Jason that used, -- on study they that benefit why have that to and for and This we
little about areas. me a Let those talk
of We and blood in points. was them campaigns cancers. data started of One hematologic cancer the growing number
that And the will our Kishor little blood a XXXX. bit here about some We focus space. talk in of cancer will continue insights into
will pediatric We also rare cancers. and in our enrich platform
recently announced the Antonio, The with Texas, Greehey the University we with As of Cancer Center. Children’s San you know, collaboration
year, We trials LP-XXX. new to LP-XXX also plan related for uncover we and opportunities studies combination on this potential where focusing expect and on immuno-oncology LP-XXX,
addition decisions the target cancer structuring the into points and poorly been our of drugs, that unnoticed data, it can subtypes focused insight to In us and uncover drug Algorithms new or can data, the to and also that on of perhaps are and algorithms automate we growth of ability rapidly patient the derisked the respond new to the library also treatment. giving algorithms critical data specific our algorithms. of RADR, because interactions. initially, only us the These course they have timeframe. datasets help but evolution us to insights, also allow finding to have they gives are data a may in allow further collection make are automate These faster potential provide ways of they gone understood and to ways us groups to over identify not correlate to even
much development of important DevOps more grows, to an what operations where of management we ensemble you the beginning especially becomes we assortment we incredible multiple algorithms parameters algorithms and also both which with is are algorithms are have and potential with are increasingly, algorithms in approach machine it when use the together. our using environment. such This used algorithms, thousands is environment, of of management are using data because Now, complex, embedded of an as learning
up into have or algorithms ability our So make certain that we weaknesses to using algorithms. multiply get other for by greater precision
we to add long-term We for advantage deepen our will be strategic antibody important significantly this two as is capabilities this develop to increasing the combination and investors. therapies. or approval number of value drug of have conjugates of in areas, diagnostic companion think an will a because this it and a to and a of define and bringing getting market to critical develop and helps combination route a help patients us and believe to approach drug both very allows patients. All that We strategy ultimately us more potential this chance faster higher a a
his in of of of were about other was also trials of that clinical many drug accelerating our over reducing indications This mentioned, an our hallmark we XX,XXX study, reviewed and ago multiple our process. -- our to Now get and with area rates The to with by was trials based evidence It ability meaningful times and a of real of as which patients. at ago and is X can potential success to costs years candidates had further had by study turning signatures, are XX that team importance. rates team did that not development to year study biomarkers we clinical there candidates times XXX he few use I a going -- very encourages this -- about Jason trials was than our reviewed University increase a And that us there success is biomarkers. Dr. crossed can a conducted He that this the drug concluded clinical a have after RADR was biomarker Toronto. trials Parker and way drug published that recent this programs. think platform utilizing showed those our -- candidates higher those drug biomarker clear
you value derisk that interest learning and solutions, and there’s techniques, kinds combination that the witness for think powered greater therapies and we techniques have or AI for machine a will be growing investor Many in appetite the by the of development are companies, or to help of especially bigger We or solutions of these firsthand yield solutions. ones these and As ultimately, data precision AI us. know, industry growing believe by therapies. machine learning we begun innovate powered adopted biopharma increasingly approaches
to briefly the the year our development to Now, over drug David call and XXXX financial candidates. to I results, our of this before discuss talk into of some in about want passing highlights
multiple in in also and positive a drug for rare in LP-XXX XXXX, glioblastoma During cancer advanced our cancer we programs. data areas we pediatric preclinical We ATRT. reported had where pancreatic
non-small that responding failed Phase cell in cancers be that been metastatic has will overall and resistant more a Phase cancer. We about Phase could a therapy is at our looking arm actually advanced the median be assessment be arms, will talk trial LP-XXX XX doubling The the of -- fourth clinical patient castration arm. other with found free randomized sites looking will X than of data sensitive and prostate X cancer. line that co X castration prostate in that be next we nine to administered Harmonic there initial bit drug resistant to later we This XX phase TKI the be clinical to little XX, X also also also one patients other from will metastatic patients of been of and Harmonic be trial survival that program or dosed several are along trial. LP-XXX cancer. lung be that of trial in in at and cohort We the will that overall never-smokers other actually have for months, co-endpoints trial, will We X this the have to trials which and survival. very target control with and LP-XXX has ratio, XX The fifth the stop arm a clinical began for two for and progression an chemo where a trials patients XX.X today, one that also survival higher share done will to the
late and cell on and plan as data research cancers year rare later ASH We including cancers, lymphomas. our program. mantle that this announced new hit drug positive LP-XXX, data on for collaborations drug additional presented blood also several year We at program this lymphoma sharing such last double in hematologic also
rare all an glioblastoma and They were for a additionally $XXX protection of of our and based pediatric potentially quite also encouraging designations orphan drug they insight commercial development. in As designation. LP-XXX, ATRT, AI Also, rapidly for the here we fees, of us our three of regards our increased to both in -- a AI sell us the -- cancer, can were Both $XXX orphan because were registration approach. us all the standing give these have driven are orphan marketing voucher result results drug designations trials This achieved of in burden waiver designation million. in fees. data we important give actually upon these approval, approach. these that and driven done to got machine learning and algorithms our where granted pancreatic drug on give U.S., us not allows from the But validation tax product we to these reduce application only credits reduce being in they massively
roadmap deficiency. excited about had abstract potentially Astrosoft of an Pancreatic submitted the physician additional conference who’s significant pancreatic AACR. a Fox virtual DNA an damage and also also NCI and the established repair also we believe we showed at an was was effective lethal prioritizing particularly first-in-class funded cancers as LP-XXX Cancer where develop Chase a area This presented very Dr. can Fox Cancer and data agent solutions that Center over Greenberg for gives showed outcomes. Chase. synthetically cancers He’s are And researcher at is in we existing it co-leader Igor that standard-of-care improvement that us with scientist for Institute We The
are University. also dollar quite will and which are responses these was good later both work now we had Hopkins X pancreatic indication for is IND us year Krieger then and hopefully trials this this IND with file Phase GBM to studies, conjunction and We studies human into in very that GBM Kennedy enabling get year. already in Johns for done long in IND This also a and the allow we and showed multi-billion in
Deep that development for us that And another patients, more trial. technology Last our best with suited technology that believe in to important collaboration. order Code ability up Harmonic in Lens two find elaborations. a our AI for to trial our also Ocean We allows announced announced collaboration We and was with our to one important securely platform. That’s we a for treatment very accelerate us year never-smokers. containerize scale
offer medicine. technology Ocean So using and believe align both ability, Deep and importantly, scale us up we of partners technology to and ways accelerate Code they more development our Lens with best-in-class are philosophy of to they both our data and the
this a More importantly, us do it allows to cost environment. efficient in
David As will through financials. walk our you
We that this of only but of collaborations a data these collaborations types out launched internally, financially bit coming the have of discipline, also very and studies have will generate and not we year. types been quite we
programs in So for but in also will not well our runway show, financial way the resources current discipline us only that a into XXXX, that CFO cash provide give part great of that, and year trials. the good development overview because our shed we programs quarter of will To on we David, full are the results. David? designing and fourth our actually more developing light financial an the our
